Robust Predictor of Breast Cancer Risk

Project: Research project

Project Details


PROJECT NARRATIVE Robust risk probability scores based on FVA analysis to identify those at increased risk for breast cancer will be a Next Generation high-throughput improvement in sensitivity and specificity, lower cost and shortened time to reporting over the current standard of cancer gene panel sequencing. Even when a mutation cannot be found by sequencing, individuals with defects in the DSB repair pathway will be faithfully identified. Direct testing of the molecular phenotypes associated with genetic defects – initiation of repair of double strand breaks in response to treatment with radiomimetic agents will circumvent the need to annotate the very frequent variants of uncertainly significance in the many genes in this pathway. The robust assays and risk scores are meant to benefit at-risk patients and their health care providers, but these tools will be of considerable use for preclinical and clinical researchers who may want to investigate the effects of exposures on increasing the risks for those with DSB repair deficiencies.
Effective start/end date7/17/206/30/22


  • National Cancer Institute: $160,000.00
  • National Cancer Institute: $2,000,000.00
  • National Cancer Institute: $991,797.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.